An hsp70 fusion protein vaccine potentiates the immune response against Japanese encephalitis virus |
| |
Authors: | F-F Ge Y-F Qiu Y-W Yang P-Y Chen |
| |
Institution: | (1) Key Laboratory of Animal Disease Diagnosis and Immunology, Ministry of Agriculture, Nanjing Agricultural University, Nanjing, P.R. China;(2) Institute of Virology, Chinese Academy of Preventive Medicine, Beijing, P.R. China |
| |
Abstract: | Summary. To evaluate the possibility of developing an effective subunit vaccine against Japanese encephalitis virus (JEV), mice were
intraperitoneally immunized with either a neutralizing epitope (a 27-amino-acid region of the JEV E protein), or with a fusion
protein between this region and a Mycobacterium tuberculosis hsp70. Both antigens were heterologously expressed in Escherichia coli as fusion proteins with thioredoxin. The fusion protein antigen elicited a higher titer of anti-thioredoxin-neutralizing
epitope antibodies and a stronger proliferation of lymphocytes than did either the neutralizing epitope (irrespective of the
presence of mineral oil as an adjuvant), or the conventional JEV SA14-14-2 vaccine. Assays of antibody isotype and IFN-γ and
IL-4 content in post-immunization serum showed that the fusion protein elicited a higher IgG2a titer and higher levels of
IFN-γ suggesting a potentiation of the Th1 immune response. The fusion protein antigen elicited a long-lived immune response,
and the antibodies were able to neutralize JEV in vitro more strongly than did those elicited by the JEV SA14-14-2 vaccine. Immunization with the fusion protein generated both humoral
and cellular immune responses to JEV, and the fusion protein appeared to be a more efficient protectant than the JEV SA14-14-2
vaccine. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|